Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical Study

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

72 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-05-20

Study Completion Date

2023-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This is a Randomized, double-blind, Placebo-Controlled, Phase II Clinical Study to evaluate SSD8432 in combination with Ritonavir in asymptomatic infections or mild/common safety study of efficacy and safety in adult subjects with COVID-19.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

To Evaluate SSD8432/Ritonavir in Adults With COVID-19

NCT05373433

COVID-19

UNKNOWN PHASE2/PHASE3

To Evaluate SSD8432/ Ritonavir in Adults With COVID-19

NCT05369676

COVID-19 Patients

COMPLETED PHASE1/PHASE2

A Clinical Study to Evaluate the Efficacy and Safety of SIM0417 Orally Co-Administered With Ritonavir in Symptomatic Adult Participants With Mild to Moderate COVID-19

NCT05506176

COVID-19

COMPLETED PHASE2/PHASE3

A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19

NCT05305547

SARS-CoV-2 Infection

COMPLETED PHASE3

Clinical Study To Evaluate The Performance And Safety Of Favipiravir in COVID-19

NCT04336904

COVID-19

UNKNOWN PHASE3

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a Randomized, double-blind, Placebo-Controlled, Phase II Clinical Study to evaluate SSD8432 in combination with Ritonavir in asymptomatic infections or mild/common safety study of efficacy and safety in adult subjects with COVID-19.

This study planned to enroll 72 subjects, randomly divided into low-dose group, high-dose group and placebo group according to 1:1:1.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

SSD8432 300mg

SSD8432 300mg in combination with ritonavir 100mg

Group Type EXPERIMENTAL

SSD8432 300mg

Intervention Type DRUG

SSD8432 300mg in combination with ritonavir 100mg, day1--day5,BID

SSD8432 750mg

SSD8432 750mg in combination with ritonavir 100mg

Group Type EXPERIMENTAL

SSD8432 750mg

Intervention Type DRUG

SSD8432 750mg in combination with ritonavir 100mg, day1--day5,BID

SSD8432 placebo

SSD8432 placebo in combination with ritonavir placebo

Group Type PLACEBO_COMPARATOR

SSD8432Placebo

Intervention Type DRUG

SSD8432Placebo in combination with ritonavir placebo,day1--day5,BID

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

SSD8432 300mg

SSD8432 300mg in combination with ritonavir 100mg, day1--day5,BID

Intervention Type DRUG

SSD8432 750mg

SSD8432 750mg in combination with ritonavir 100mg, day1--day5,BID

Intervention Type DRUG

SSD8432Placebo

SSD8432Placebo in combination with ritonavir placebo,day1--day5,BID

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

ritonavir 100mg ritonavir 100mg ritonavir placebo

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. ≥18 and ≤80 years old, male or female.
2. Asymptomatic infection,mild or common type of COVID-19.
3. Initial positive test of SARS-CoV-2 within 5 days of randomization.
4. Initial onset of COVID-19 signs/symptoms within 3 days of randomization.

Exclusion Criteria

1. Transnasal high-flow oxygen therapy or non-invasive ventilation, invasive mechanical ventilation, or ECMO is required or anticipated to be urgently required.
2. Prior to current disease episode, any confirmed SARS-CoV-2 infection.
3. Known medical history of active liver disease (other than nonalcoholic hepatic steatosis).
4. Receiving dialysis or have known moderate to severe renal impairment.
5. Known human immunodeficiency virus (HIV) infection.
6. Suspected or confirmed concurrent active systemic infection other than COVID-19 that may interfere with the evaluation of response to the study intervention.
7. Oxygen saturation of ≤ 93% on room air obtained at rest within 24 hours prior to randomization..
8. Treatment with antivirals against SARS-CoV-2 within 14 days.
9. Current or expected use of any medications or substances that are highly dependent on CYP3A4 for clearance.
10. Concomitant use of any medications or substances that are strong inducers of CYP3A4 are prohibited within 28 days.
11. Has received or is expected to receive COVID-19 monoclonal antibody, convalescent COVID-19 plasma or other prohibited concomitant medication.
12. Females who are pregnant or breastfeeding.

Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No